6
Participants
Start Date
January 31, 2012
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
Fludarabine
40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
Busulfan
130 mg/ m2 by vein for 2 doses on Days -11 to -10.
NK cell infusion:
Natural killer cell infusion will be administered by vein on Day -8.
Interleukin-2
0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
Anti-Thymocyte Globulin
2.5 mg/kg by vein for 3 doses on Days -3 to -1.
Allogeneic related Stem Cell Transplant
Allogeneic related stem cell transplant by vein on day 0.
Tacrolimus
Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
Methotrexate
5 mg/m2 by vein Days 1, 3 and 6 post transplant.
G-CSF
5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
University of Texas MD Anderson Cancer Center, Houston
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER